Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Endophthalmitis is a sight-threatening condition, and its timely and appropriate management is essential in preventing permanent vision loss. Recent changes in clinical practice in endophthalmitis and advances in modern vitreoretinal surgery may limit the applicability of established randomised clinical trial evidence to current management. This review discusses the epidemiology, pathophysiology, changing patient presentation, diagnosis and advances in the management of endophthalmitis, presenting the existing literature on this topic and results from Sydney Eye Hospital.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589908 | PMC |
| http://dx.doi.org/10.1007/s40123-021-00406-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Experience of Geographic Atrophy Treatment With Avacincaptad Pegol.
J Vitreoretin Dis
September 2025
Retina Group of Washington, Reston, VA, USA.
To present the first real-world safety data describing the clinical experience of geographic atrophy (GA) treatment with avacincaptad pegol in a large cohort. A retrospective, observational cohort study was conducted within the PRISM Vision Group by filtering for J codes for avacincaptad pegol from August 3, 2023, to October 10, 2024. The study included 461 eyes of 335 patients with GA who were treated with intravitreal avacincaptad pegol 2 mg (0.
View Article and Find Full Text PDFCost-Utility Analysis of Early Vitrectomy vs Intravitreal Biopsy and Injection for Endophthalmitis.
J Vitreoretin Dis
September 2025
The Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
To perform a cost-utility analysis comparing primary pars-plana vitrectomy (PPV) within 24 hours with primary nonsurgical vitreous tap (or tap and inject [T&I]) for the management of endophthalmitis. Retrospective cost-utility analysis using decision tree modeling. The Victorian Endophthalmitis Registry was used to model outcome probabilities and costs from a third-party payer perspective.
View Article and Find Full Text PDFTemporal B-Scan Ultrasonography Findings and their Relation to Visual Outcomes in Endophthalmitis.
J Vitreoretin Dis
September 2025
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
To evaluate B-scan echographic features of endophthalmitis for their correlation with disease characteristics and long-term vision outcomes. Patients diagnosed with endophthalmitis at Massachusetts Eye and Ear between 2011 and 2021 were recruited (N = 209). Data included demographics, infection source, initial therapy, and findings from culture isolates, best corrected visual acuity (BCVA), slit lamp, and B-scan ultrasonography.
View Article and Find Full Text PDFAssociation of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis.
Ophthalmol Retina
September 2025
The University of Ottawa Eye Institute, Ottawa, Ontario, Canada. Electronic address:
Objective: Anti-vascular endothelial growth factor (VEGF) therapies have transformed the management of neovascular age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion (RVO). This class-wide pharmacovigilance study evaluated the disproportionality of reported ocular adverse events (AEs) among anti-VEGF agents using real-world data.
Design: A population-based, observational pharmacovigilance study.
Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.
Retina
August 2025
Department of Ophthalmology, University of Illinois at Chicago and Illinois Eye and Ear Infirmary, Chicago, IL.
Purpose: To investigate the potential utility of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).
Methods: Retrospective review of anatomic and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.
Results: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received 2 both bevacizumab and aflibercept).